DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
NEW YORK, April 05, 2017 -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech, is scheduled to meet with business prospects and investors at BioCentury’s annual Future Leaders in the Biotech Industry Conference on April 7, 2017 at the Millennium Broadway Hotel & Conference Center in New York City.
Now in its 24th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
AXIM Biotech’s presentation will be available on April 7th at this link.
About AXIM®
AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Public Relations Contact Andrew Hard Chief Executive Officer CMW Media [email protected] P. +1888 829-0070 www.cmwmedia.com Investor Relations Contact Shiwei Yin, Grayling [email protected] P. +1646 284-9474 Lucia Domville, Grayling [email protected] P. +1646 284-9416 Corporate Contact Info North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
